关于公司被认定为国家级专精特新"小巨人"企业的 自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、基本情况 近日，北京热景生物技术股份有限公司（以下简称"公司"）获得了由中华 人民共和国工业和信息化部（以下简称"工信部"）颁发的国家级专精特新"小 巨人"企业证书，入选工信部第七批国家级专精特新"小巨人"企业。 证券代码：688068 证券简称：热景生物 公告编号：2025-083 北京热景生物技术股份有限公司 2025 年 11 月 25 日 2 二、对公司的影响 国家级专精特新"小巨人"企业是工信部为贯彻落实中共中央办公厅、国务 院办公厅《关于促进中小企业健康发展的指导意见》等有关要求，经各省级主管 部门通过组织报送、专家评审、社会公示等流程而评选产生。专精特新"小巨人" 企业通常位于产业基础核心领域、产业链关键环节，创新能力突出、掌握核心技 术、细分市场占有率高、质量效益优，是优质中小企业的核心力量。 公司此次被认定为国家级专精特新"小巨人"企业，是对公司科研技术、创 新能力、发展前景、产品质量、行业地 ...

热景生物公告称，公司获工信部颁发的国家级专精特新"小巨人"企业证书，入选第七批该类企业。专精 特新"小巨人"企业经多流程评选产生，是优质中小企业核心力量。此次认定是对公司综合实力的认可， 利于提升品牌知名度与核心竞争力，对整体业务发展有积极影响。不过，该认定不会对当期经营业绩产 生重大影响。 ...

智通财经APP讯，热景生物(688068.SH)发布公告，近日，公司获得了由中华人民共和国工业和信息化 部(简称"工信部")颁发的国家级专精特新"小巨人"企业证书，入选工信部第七批国家级专精特新"小巨 人"企业。 公司此次被认定为国家级专精特新"小巨人"企业，是对公司科研技术、创新能力、发展前景、产品质 量、行业地位等综合实力的充分认可，有利于提升公司的品牌知名度与核心竞争力，对公司整体业务发 展产生积极影响。 ...

公司此次被认定为国家级专精特新"小巨人"企业，是对公司科研技术、创新能力、发展前景、产品质 量、行业地位等综合实力的充分认可，有利于提升公司的品牌知名度与核心竞争力，对公司整体业务发 展产生积极影响。 热景生物(688068.SH)发布公告，近日，公司获得了由中华人民共和国工业和信息化部(简称"工信部")颁 发的国家级专精特新"小巨人"企业证书，入选工信部第七批国家级专精特新"小巨人"企业。 ...

Group 1 - The company has approved a share repurchase plan using its own funds, with a total repurchase amount between RMB 100 million and RMB 200 million, and a maximum repurchase price of RMB 244 per share [1] - As of the announcement date, the company has repurchased a total of 904,054 shares, accounting for 0.98% of the total share capital, with the highest transaction price at RMB 176.79 per share and the lowest at RMB 145.59 per share, totaling RMB 149,955,134.73 spent [2] - The share repurchase progress complies with legal regulations and the company's repurchase plan [3] Group 2 - The company will strictly follow relevant regulations and guidelines during the repurchase period and will make repurchase decisions based on market conditions, ensuring timely information disclosure regarding the progress of the share repurchase [4]

Group 1 - The core point of the news is that 热景生物 has repurchased approximately 900,000 shares, which is about 0.98% of its total share capital, with a total expenditure of approximately 150 million RMB [1] - The share repurchase was conducted through centralized bidding, with the highest transaction price being 176.79 RMB per share and the lowest at 145.59 RMB per share [1] - As of the announcement date, the market capitalization of 热景生物 is 15.2 billion RMB [2] Group 2 - For the fiscal year 2024, the revenue composition of 热景生物 is primarily from in vitro diagnostic products, accounting for 98.85%, while other businesses contribute 1.15% [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：688068 证券简称：热景生物 公告编号：2025-082 北京热景生物技术股份有限公司 关于以集中竞价方式回购股份进展的自愿性披露公告 截至本公告披露日，公司通过股份回购专用证券账户，以集中竞价交易方式 累计回购股份 904,054 股，占公司总股本 92,707,940 股的比例为 0.98%，回购成 交的最高价为 176.79 元/股，最低价为 145.59 元/股，支付的资金总额为人民币 149,955,134.73 元（不含印花税、交易佣金等交易费用）。 本次回购股份进展符合法律法规的规定及公司回购股份方案。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特此公告。 北京热景生物技术股份有限公司董事会 2025 年 11 月 24 日 重要内容提 ...

Core Insights - The article highlights the innovative practices of domestic pharmaceutical companies in China, particularly focusing on the advancements made by Realtime Biotech and Tailong Pharmaceutical in the context of the rapidly evolving industry [1][2]. Company Developments - Realtime Biotech, founded by Lin Changqing in 2005, has evolved from an in vitro diagnostic (IVD) company to a biopharmaceutical enterprise, marking a significant transition in its business model [1]. - Tailong Pharmaceutical emphasizes the modernization of traditional Chinese medicine through innovative practices, showcasing the integration of ancient techniques with modern technology in its production processes [1]. Industry Trends - The exploration by Realtime Biotech and Tailong Pharmaceutical reflects the broader trend of innovation within China's biopharmaceutical industry, indicating a shift towards more advanced and diversified medical solutions [2].

Core Viewpoint - The company, as the first IVD listed enterprise on the Sci-Tech Innovation Board, is transitioning from in vitro diagnostics to biopharmaceuticals, aligning with national biomanufacturing strategies and focusing on long-term growth in the biopharmaceutical sector [1][2] Group 1: Industry Trends and Strategic Positioning - Biomanufacturing is recognized as a strategic emerging industry for the next decade, with biopharmaceuticals being a key battleground due to high technical barriers [2] - The company's expansion from in vitro diagnostics to biopharmaceuticals is seen as a natural extension of its core biotechnological competencies, emphasizing the interconnectedness of diagnostic and therapeutic technologies [2] - The company has made significant investments in basic research, publishing multiple papers in top journals and establishing a solid R&D framework [2] Group 2: Innovation and Product Development - The company adheres to the "uniqueness and firstness" principle in its innovation pipeline, focusing on early screening for liver cancer and developing cutting-edge technologies in the field [4][5] - The company’s liver cancer early screening products are widely used in high-risk populations and have been included in expert consensus, contributing to early detection and treatment [4] - The company is also developing the world's first antibody drug for myocardial infarction, which has completed Phase I clinical trials and is preparing for Phase II [5] Group 3: Global Market Expansion - The company has initiated overseas expansion since 2019, achieving over 600 foreign certifications and establishing a presence in Southeast Asia, South Asia, the Middle East, and Latin America [6] - The company aims to provide high-quality, cost-effective medical products to developing countries, enhancing global health equity [6] - The company plans to increase its efforts in overseas market development, leveraging its strong technical capabilities and certification reserves [6] Group 4: Financial Commitment to R&D - The company's R&D investment as a percentage of revenue has been significant, with 24.29% in 2023, 22.18% in 2024, and 23.45% in the first half of 2025 [8]

Group 1 - The core point of the news is that 热景生物 (Hotgen Biotech) experienced a decline of 5.13% in its stock price, reaching 163.17 CNY per share, with a trading volume of 1.18 billion CNY and a market capitalization of 15.127 billion CNY [1] - Hotgen Biotech, established on June 23, 2005, and listed on September 30, 2019, specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments. The revenue composition is as follows: testing reagents 70.87%, testing instruments 19.79%, others 8.17%, and biological raw materials 1.17% [1] Group 2 - 中航优选领航混合发起A (CASC Optimal Selection Mixed Fund A) has increased its holdings in Hotgen Biotech by 53,100 shares in the third quarter, bringing the total to 290,100 shares, which constitutes 11.14% of the fund's net value, making it the fourth-largest holding [2] - The fund has reported a floating loss of approximately 2.5616 million CNY as of the latest data [2] - The fund manager, 王森 (Wang Sen), has been in charge for 2 years and 55 days, with the fund's total asset size at 2.85 billion CNY. The best return during his tenure is 132.1%, while the worst return is -0.6% [3]